Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
The phenotype of peripheral blood lymphocytes of 27 renal cell carcinoma patients before and at the end of subcutaneously given rIL-2 therapy was determined by two colour flow cytometry. Therapy induced changes in peripheral blood leucocyte composition and phenotypes were comparable to those reported for intravenously given rIL-2. The present paper shows a correlation between the 'activation status' of the patient before therapy and eventual response.
Janssen
R A
RA
Department of Clinical Immunology, University Hospital Groningen, The Netherlands.
Sleijfer
D T
DT
Heijn
A A
AA
Mulder
N H
NH
The
T H
TH
de Leij
L
L
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000097:blood* / Q000276:immunology / Q000628:therapy; D007958:Leukocyte Count; D016131:Lymphocyte Subsets; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011994:Recombinant Proteins / Q000008:administration & dosage
D007376:Interleukin-2; D011994:Recombinant Proteins